ArticleFrontiers in oncology2019
Dabrafenib and Trametinib in BRAF Mutant Metastatic Conjunctival Melanoma.
Article in Frontiers in oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 46 citations in OpenAlex.
- Conjunctival melanoma genomic analysis reveals intermediate tumor mutation burden and genomic overlap with cutaneous melanoma.NPJ precision oncology · 2025Article
- [New systemic treatment approaches for conjunctival melanoma].Die Ophthalmologie · 2025Review
- Emerging Techniques in the Treatment of Conjunctival Melanoma.Current ophthalmology reports · 2025Review
- Conjunctival melanoma: comprehensive insights into clinical features, genetic alterations, and modern treatment approaches.Pathology oncology research : POR · 2025Review
- Conjunctival Melanoma: A Clinical Review and Update.Cancers · 2024Review
- Biological characteristics and clinical management of uveal and conjunctival melanoma.Oncology research · 2024Review
- Review
- BRAF and NRAS prognostic values in conjunctival melanoma: analysis and literature review.Arquivos brasileiros de oftalmologia · 2023Article
- Cucurbitacin B-induced G2/M cell cycle arrest of conjunctival melanoma cells mediated by GRP78-FOXM1-KIF20A pathway.Acta pharmaceutica Sinica. B · 2022Article
- New Therapeutic Approaches for Conjunctival Melanoma-What We Know So Far and Where Therapy Is Potentially Heading: Focus on Lymphatic Vessels and Dendritic Cells.International journal of molecular sciences · 2022Review
- Small but Challenging Conjunctival Melanoma: New Insights, Paradigms and Future Perspectives.Cancers · 2021Review
- Article
- A Drug Screening Pipeline Using 2D and 3D Patient-Derived In Vitro Models for Pre-Clinical Analysis of Therapy Response in Glioblastoma.International journal of molecular sciences · 2021Article
- Efficacy of immune checkpoint inhibitors in different types of melanoma.Human vaccines & immunotherapeutics · 2021Article
- Current Management of Conjunctival Melanoma Part 2: Treatment and Future Directions.Turkish journal of ophthalmology · 2020Review
- Review
- Genetic Biomarkers in Melanoma of the Ocular Region: What the Medical Oncologist Should Know.International journal of molecular sciences · 2020Review
- Conjunctival Melanoma: Update on Genetics, Epigenetics and Targeted Molecular and Immune-Based Therapies.Clinical ophthalmology (Auckland, N.Z.) · 2020Review
- Management Issues in Conjunctival Tumours: Conjunctival Melanoma and Primary Acquired Melanosis.Ophthalmology and therapy · 2019Review
- Conjunctival Melanoma: Genetic and Epigenetic Insights of a Distinct Type of Melanoma.International journal of molecular sciences · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Conjunctival melanoma is a rare primary ocular tumor. So far, no standard treatment exists for metastatic disease. Similarly to cutaneous melanoma, up to 50% of conjunctival melanomas harbor BRAF mutations. The most common is represented by V600E. Combined therapy with BRAF and MEK inhibitors is approved for BRAF mutant cutaneous metastatic melanomas. Herein, we report a case of a 70-years old patient with a metastatic conjunctival melanoma harboring V600E BRAF mutation successfully treated with dabrafenib and trametinib.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.